Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

PLP (139-151)

Copy Product Info
😃Good
Catalog No. TP1282Cas No. 131334-43-5
Alias PLP 139-151

PLP (139-151) is an amino acid fragment from positions 139 to 151 of myelin proteolipid protein (PLP), which is used to induce the relapsing-remitting experimental autoimmune encephalomyelitis (RR-EAE) model.

PLP (139-151)

PLP (139-151)

Copy Product Info
😃Good
Catalog No. TP1282Alias PLP 139-151Cas No. 131334-43-5
PLP (139-151) is an amino acid fragment from positions 139 to 151 of myelin proteolipid protein (PLP), which is used to induce the relapsing-remitting experimental autoimmune encephalomyelitis (RR-EAE) model.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
1 mg$85InquiryInquiry
5 mg$355InquiryInquiry
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Resource Download

Product Introduction

Bioactivity
Description
PLP (139-151) is an amino acid fragment from positions 139 to 151 of myelin proteolipid protein (PLP), which is used to induce the relapsing-remitting experimental autoimmune encephalomyelitis (RR-EAE) model.
Disease Modeling Protocol
Experimental autoimmune encephalomyelitis (EAE) model
  • Modeling Mechanism:

    Transgenic mice with the PLP 139-151 epitope-specific T-cell receptor (TCR) exhibit peripheral CD4⁺ T cells that recognize the PLP-139-151/I-Aᵏ complex in the myelin sheath of the central nervous system (CNS). Without thymic tolerance deletion, these cells spontaneously or through induction activate and infiltrate the CNS, releasing Th1 cytokines such as IFN-γ, triggering inflammatory infiltration and demyelination damage, leading to acute exacerbation encephalitis (EAE). Non-encephalogenic TCRs (4E3 clones) exhibit a higher frequency of spontaneous disease due to their higher affinity for PLP-139-151/I-Aᵏ.

  • Related Products:

    PLP (139-151) (TP1282)

  • Modeling Method:

    Experimental Subject:Mice: SJL/J (H-2ˢ background), FVB/N (transgenic founder background), RAG-2 deficient SJL/J; 6–8 weeks of age

    Dosage and Administration Route:① Spontaneous model: No administration; natural onset in SPF/VAF environment; ② Induced model: 25 μg PLP-139-151 peptide emulsified in complete Freund's adjuvant (CFA) containing 400 μg Mycobacterium tuberculosis, administered subcutaneously; 75 ng pertussis toxin (PT), administered intravenously; ③ PT-only induction: intravenous injection of 75 ng PT alone

    Dosing Frequency and Duration Model:In the induced model, PLP/CFA+PT was injected on day 0, with PT repeated on day 2; in the PT-only group, PT was injected once on days 0 and 2

  • Validation:

    Clinical phenotype: A 0-5 scoring system was used (0 = no disease, 1 = tail weakness, 2 = gait abnormality/impaired righting reflex, 3 = complete hind limb paralysis, 4 = quadriplegia, 5 = near death); the spontaneous morbidity rate in 5B6 TCR transgenic mice was 40% (N₂-N₆ generation), while the morbidity rate in 4E3 TCR transgenic mice reached 60%-83% (N₃-N₅ generation); the induced morbidity rate was 7/7 (PLP/CFA+PT) and 5/6 (PT alone), with the onset of disease occurring earlier in 5B6 transgenic mice than in non-transgenic mice (7.2 days vs. 14.5 days); Histological markers: Numerous inflammatory foci were observed in the CNS (brain and spinal cord), with CD4⁺Vβ6⁺ T cell infiltration being the predominant feature in 5B6 transgenic mice, while no inflammation was observed in non-transgenic mice; Molecular markers: Splenic cells proliferated rapidly after stimulation with PLP-139-151, secreting large amounts of IFN-γ. Released IL-2, but no IL-4/IL-10/TNF-α; flow cytometry detected high expression of transgenic Vβ6 in peripheral CD4⁺ T cells (5B6 mice > 98%).

*Precautions: Brain and spinal cord tissues were collected from all mice at the time of sacrifice and fixed in 10% formalin or OCT and frozen.

*References:Waldner H,et,al. Fulminant spontaneous autoimmunity of the central nervous system in mice transgenic for the myelin proteolipid protein-specific T cell receptor. Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3412-7.

SynonymsPLP 139-151
Chemical Properties
Molecular Weight1537.79
FormulaC72H104N20O16S
Cas No.131334-43-5
SmilesC([C@H](NC([C@@H](NC(CNC([C@@H](NC([C@@H](NC([C@H](CC1=CN=CN1)N)=O)CS)=O)CC(C)C)=O)=O)CCCCN)=O)C(N[C@H](C(NCC(N[C@H](C(=O)N2[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CC3=CC=CC=C3)C(O)=O)=O)CCCCN)=O)CC(O)=O)=O)CCC2)CC4=CN=CN4)=O)=O)CC(C)C)=O)C=5C=6C(NC5)=CC=CC6
Relative Density.1.332 g/cm3 (Predicted)
SequenceH-His-Cys-Leu-Gly-Lys-Trp-Leu-Gly-His-Pro-Asp-Lys-Phe-OH
Sequence ShortHCLGKWLGHPDKF
Storage & Solubility Information
Storagekeep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
H2O: 50 mg/mL (32.51 mM), Sonication is recommended.
Solution Preparation Table
H2O
1mg5mg10mg50mg
1 mM0.6503 mL3.2514 mL6.5028 mL32.5142 mL
5 mM0.1301 mL0.6503 mL1.3006 mL6.5028 mL
10 mM0.0650 mL0.3251 mL0.6503 mL3.2514 mL
20 mM0.0325 mL0.1626 mL0.3251 mL1.6257 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy PLP (139-151) | purchase PLP (139-151) | PLP (139-151) cost | order PLP (139-151) | PLP (139-151) chemical structure | PLP (139-151) formula | PLP (139-151) molecular weight